Quote:"Is leronlimab, an unapproved drug, currently available to the public outside of a clinical trial?
As an unapproved drug, leronlimab is not available to the general public. However, certain patients who are facing serious illnesses, and who have exhausted all available treatment options, may be able to receive early access to investigational drugs that haven’t yet been approved by government regulatory agencies. The FDA allows for two options for treating patients with an unapproved drug, biologic or test article outside of a clinical trial. One option is “ Expanded Access .” The other option is “ Right to Try .” For additional information about potentially obtaining leronlimab, through your medical provider, under an Expanded Access allowance, please feel free to email: dai@cytodyn.com.
For the most up-to-date information regarding The Right to Try Act , and/or potential access for patients who have been diagnosed with life-threatening diseases or conditions, have tried all approved treatment options, and are unable to participate in a clinical trial to access certain investigational treatment options, please visit FDA.gov and review its overview regarding “Right to Try” allowances. https://www.fda.gov/patients/learn-about-expa.../right-try
WARNING: Leronlimab has not received regulatory approval from the FDA. The potential risks and benefits are not known. Doctors and patients should consider all possible benefits and risks before applying for expanded access (or right to try) to leronlimab."
From the Frequently Asked Questions "Is leronlimab, an
Top 10 Most Recent News Articles
IASLC Boosts Global Thoracic Cancer Collaboration
Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...
Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer
Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...
Continue Reading
USPS Honors 150 Years of the U.S. Coast Guard Academy
Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...
Continue Reading
Damp or Dry: The Battle for Healthy Air in Colorado
The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...
Continue Reading
Larry Ellison's Moves Signal Confidence in Oracle's Future
Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...
Continue Reading
PathoSearch: A New Era in Pathology With Visual Search
Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....
Continue Reading
Pizza: The Unlikely Symbol of Universal Togetherness
Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...
Continue Reading
Delhi Pushes Innovation Against Dryland Challenges
Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...
Continue Reading
PureHealth's Acid Reflux Solutions: An Investor's Insight
Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...
Continue Reading
New 2027 Jeep Wrangler JL-2A: A Blast from the Past
Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...
Continue ReadingTop 5 Most Recently Viewed Articles
CGI Reports Impressive 9.7% Revenue Growth in Q4-F2025
CGI Announces Strong Financial Results for Fourth Quarter Canadian IT and consulting giant CGI Inc. just released its fourth quarter and Fiscal 2025 results, showcasing a remarkable revenue growth of 9.7% year-over-year, amounting to $4.01 billion. This substantial increase in revenue reflects the effectiveness of CGI's strategic initiatives in a rapidly changing...
Continue Reading
Y-mAbs Prepares for Significant R&D Update on Radiopharmaceuticals
Y-mAbs: A Pioneering Force in Radiopharmaceutical Innovation Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) continues to be at the forefront of biopharmaceutical innovation, particularly in the realm of radiopharmaceuticals. The company's latest announcement has generated buzz within the medical community as it announces a virtual Radiopharmaceutical Research and Development...
Continue Reading
TechnipFMC Earnings Preview: Trader Tension Ahead of EPS Drop?
TechnipFMC (NYSE:FTI) is set to roll out its quarterly earnings report on February 19, 2026, and desks are buzzing with anticipation—but not all that glitters is gold. Analysts are calling for an earnings per share (EPS) of $0.51, which might sound reasonable until you dig into the history here. The last quarter? TechnipFMC beat expectations by a mere $0.10—and still...
Continue Reading
Asetek's Q3 Performance Signals Future Growth Potential
Asetek's Latest Financial Results Asetek has reported its financial results for the third quarter of 2025, noting a revenue of $9.8 million. This figure shows a decline compared to the $12.2 million reported in the same quarter of 2024. The company has faced fewer shipments of liquid cooling products, which has significantly affected revenue over these periods. Gross...
Continue Reading
Toronto Hydro's Financial Growth: Third Quarter Insights Revealed
Toronto Hydro Corporation Reports Financial Growth for Q3 Toronto Hydro Corporation (Toronto Hydro) has recently unveiled its financial and operational results for the third quarter of 2025, marking a period of notable growth and strategic investment. During this quarter, net income after adjustments surged to $178.1 million, reflecting an impressive increase of $56.8...
Continue Reading